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Abstract Glucocorticoid induced tumor necrosis factor receptor
(GITR) is a new member of the tumor necrosis factor^nerve
growth factor receptor superfamily of which the function has not
been well studied. The extracellular domain of GITR was
produced in Escherichia coli and purified as a single band of
predicted Mr of 18.0 kDa. GITR and GITR ligand were
expressed constitutively on the surface of Raw 264.7 macro-
phage cell line and murine peritoneal macrophages. An
extracellular domain of GITR can activate murine macrophages
to express inducible nitric oxide synthase and to generate nitric
oxide in a dose- and time-dependent manner. ß 2002 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Glucocorticoid induced tumor necrosis factor receptor
(GITR) is a member of the tumor necrosis factor receptor
(TNFR) family induced by dexamethasone in murine T cells
and may play a role in protecting T cells from activation
induced cell death [1]. GITR shares a common motif with
the TNFR family in the extracellular domain which has multi-
ple cysteine-rich pseudorepeats [2] and shows close similarity
in amino acid sequence with the cytoplasmic domains of
4-1BB,CD27, AITR [3^5]. This subfamily is implicated in di-
verse biological functions such as costimulation for T cell
activation [6^8], and inhibition of activation induced cell
death [9,10]. Recently signal transduction pathways for these
molecules have been reported [11^13]. 4-1BB, AITR, and
CD27 associate with TRAF2 to initiate a signal cascade for
activation of nuclear factor UB (NF-UB). Little is known
about the function of GITR.
Macrophages play key roles during immune response after
activation [14]. Macrophages can kill bacteria, viruses, or par-
asites directly, secrete proin£ammatory cytokines, act as anti-
gen presenting cells, and ¢nally participate in tissue remodel-
ing. In the case of septic shock, they also release
proin£ammatory cytokines and nitric oxide (NO) and lead
to severe systemic in£ammation [15,16]. NO and TNF-K are
considered primary mediators for pathogenesis of endotoxic
shock related to development of circulatory failure, multior-
gan failure, and ultimately death [17,18]. NO has been iden-
ti¢ed as an important signaling molecule involved in regulat-
ing a variety of biological activities. Macrophages release NO
from the guanidino moiety of L-arginine via a reaction cata-
lyzed by the inducible form of nitric oxide synthase (iNOS) by
a variety of agents such as endotoxin, interleukin (IL)-1,
TNF, and Q-interferon (IFN-Q) [19].
In this study, we report that macrophages express constitu-
tively GITR and GITR ligand. Stimulation of macrophages
with recombinant soluble GITR induced signi¢cant amounts
of NOS with production of NO.
2. Materials and methods
2.1. Cells
Raw 264.7 cells, a murine macrophage cell line, were obtained from
the ATCC and cultured in Dulbecco’s modi¢ed Eagle’s medium sup-
plemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 Wg/
ml streptomycin in six-well plates or in 10-cm dishes. Thioglycollate-
elicited peritoneal macrophages were obtained from C57BL/6 mice
which received 2 ml of 2% thioglycollate i.p. 4 days before. Cells
were harvested by lavage of the peritoneal cavity with 6 ml of Hanks’
solution.
2.2. Production of recombinant extracellular domain of GITR in
Escherichia coli
The putative extracellular portion of GITR cDNA was ampli¢ed by
the pfu polymerase chain reaction (PCR). An NheI site was generated
at the 5P end of the forward primer and an XhoI site and a stop codon
were in the reverse primer. The sequence of the forward primer was
5P-ATCTAGCTAGCCAGCCGAGTGTAGTTGAG-3P, and that of
the reverse primer was 5P-ATCCGCTCGAGGCCGTATTGCT-
CAGTGGG-3P. The PCR product was digested by NheI and XhoI
and theV0.4-kb fragment was puri¢ed. The NheI^XhoI fragment was
inserted into the NheI/XhoI-digested pET28a vector, generating pET-
GITR. The pET-GITR plasmid DNA was prepared and used to
transform the E. coli BL21 expression strain (Novagen). The bacteria
were grown at 37‡C until the optical density at 600 nm reached 0.6^
0.8. Isopropyl 1-thio-L-D-galactopyranoside (IPTG) was added to a
¢nal concentration of 0.4 mM and the incubation continued at 37‡C
for an additional 6 h. To purify the GITR protein, bacteria were
harvested by centrifugation, pellets were washed twice in bu¡er A
containing 20 mM Tris^HCl, pH 7.5, 10 mM EDTA, and 2% Triton
X-100, and homogenized using a sonicator for 3 min. Homogenate
was dissolved in bu¡er A, stirred for 30 min at room temperature, and
centrifuged. The pellet containing inclusion body was washed three
times, and was stirred for 30 min in bu¡er B containing 50 mM Tris^
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HCl, pH 8.5, 1% sodium dodecyl sulfate (SDS), and 1 mM 2-mercap-
toethanol. The pellet was washed three times, dissolved in a bu¡er
containing 10 mM Tris, pH 8.0, 6 M guanidine thiocyanate, 0.1%
Triton X-100, and 5 mM 2-mercaptoethanol, and was homogenized
for 3 min using a Branson soni¢er 450 (Danbury, CT, USA). The
supernatant was dialyzed sequentially against 2.4 M, 0.5 M, 0.1 M
and 0 M of guanidine thiocyanate with 2-mercaptoethanol each for
3 h. Finally the renatured GITR protein was concentrated, treated by
ultra¢ltration with bu¡er exchange with phosphate based saline, and
stored at 370‡C.
2.3. Antibodies
The anti-GITR monoclonal antibody (mAb) mAH7 was produced
by immunizing 7-week-old Sprague^Dawley rats with 50 Wg of re-
combinant (r) soluble GITR emulsi¢ed in Freund’s complete adju-
vant. Rats received three consecutive i.v. injections at 2-week inter-
vals. Four days after the last i.v. injection via the tail, the rat was
killed and its spleen was removed. Spleen cells were fused with rat
myeloma cells and the hybridoma supernatants were screened by en-
zyme-linked immunosorbent assay (ELISA) for GITR using puri¢ed
histidine-tagged GITR protein. Twenty-four clones were isolated and
subcloned. One clone, mAH7, was characterized and used in the
present studies. Isotyping of mAb was performed by using the Immu-
nopure Monoclonal Antibody Isotyping kit (Pierce, Rockford, IL,
USA).
For polyclonal antiserum against GITR, rabbits were immunized
with puri¢ed rGITR (100 Wg/dose) emulsi¢ed in Freund’s complete
adjuvant. Rabbits received three consecutive s.c. injections in the back
at 2-week intervals. The serum was obtained 2 weeks after the ¢nal
injection. The titer was measured by ELISA and Western blot.
2.4. Immunoblot analysis
Cell lysate (50 Wg) was separated by SDS^polyacrylamide gel elec-
trophoresis (PAGE) and transferred onto nitrocellulose membranes as
described [20]. The blots were then washed in Tris^Tween bu¡ered
saline (TTBS, 20 mM Tris^HCl, pH 7.6 containing 137 mM NaCl and
0.05% (v/v) Tween 20), blocked overnight with 5% (w/v) bovine serum
albumin (BSA), and probed with mAb for iNOS in 5% (w/v) BSA
dissolved in TTBS. Using horseradish peroxidase conjugated second-
ary anti-mouse Abs (iNOS) were detected by enhanced chemilumines-
cence.
2.5. Flow cytometry
Cells (5U105/sample) were incubated in PFS bu¡er (phosphate
based saline, 2.5% fetal bovine serum, and 0.1% sodium azide) with
puri¢ed histidine-tagged GITR (none: isotype control) or anti-GITR
polyclonal Ab (preimmune serum: isotype control) on ice for 30 min
for detection of GITR ligand and GITR, respectively. Cells were
washed three times in PFS, and incubated on ice for 30 min with
mouse anti-His Ab for detection of GITR ligand. Cells were then
incubated on ice for 30 min with FITC-conjugated goat anti-mouse
IgG or FITC-conjugated goat anti-rabbit IgG for detection of GITR
ligand and GITR, respectively. The cells were washed again as above
and £ow cytometry was performed using a FACSCalibur (Becton
Dickinson).
2.6. Determination of NO32 concentration
NO32 production in culture supernatants was assayed by measuring
nitrite, its stable degradation product, using Griess reagent. After
stimulation, the supernatants were centrifuged and aliquots were
mixed with 0.25 ml of Griess reagent to make a ¢nal volume of
0.5 ml and then incubated for 10 min at room temperature before
measuring the absorbance at 540 nm. NaNO2 was used as a standard.
3. Results
3.1. Expression and puri¢cation of recombinant GITR from
E. coli
Extracellular domain of GITR was produced in E. coli by
cloning mouse GITR cDNA into the IPTG-inducible pET28a
expression plasmid. The rGITR fusion protein with polyhis-
tidine tag was found in the inclusion body. The rGITR was
puri¢ed by extensive serial washings, denaturation, and rena-
turation. Approximately 14 mg of GITR per liter of E. coli
culture was obtained. Purity of GITR was veri¢ed by the
appearance of a single band of predicted Mr of 18.0 kDa by
SDS^PAGE (Fig. 1). The Mr of the rGITR was 37 kDa in
non-denaturing condition. This preparation was used for gen-
eration of polyclonal rabbit anti-GITR Ab and identi¢cation
of GITR ligand by FACS. In some experiments the rGITR
was puri¢ed by eluting the protein from 10% SDS^PAGE to
avoid possible endotoxin contamination. This procedure en-
abled us to purify 1.3 mg of GITR per liter of E. coli culture.
SDS gel-puri¢ed rGITR contained no more than a trace
amount of endotoxin (6 0.4 EU/mg by the E-Toxate assay
from Sigma Chemical).
3.2. Expression of GITR and GITR ligand in murine Raw
264.7 macrophages
We examined the presence of GITR ligand in macrophages
to transmit the signal by soluble GITR. FACS analysis indi-
cated that low levels of GITR and GITR ligand were ex-
pressed constitutively on the surface of the Raw 264.7 macro-
phage cell line and murine peritoneal macrophages as shown
in Fig. 2A,B, respectively. For detection of GITR, mAH7 was
also tried, but the peak shift was smaller than with polyclonal
anti-GITR Ab, probably due to its low a⁄nity (data not
shown).
3.3. Production of NO and induction of NOS by GITR
Macrophages incubated with soluble GITR expressed a
high level of iNOS and produced a signi¢cant amount of
NO in a dose-dependent manner (measured as NO32 ) (Fig.
3). Production of NO32 was detectable at 10 ng/ml of GITR
after 24 h stimulation. Above 100 ng of GITR activation, the
level of NO32 reached a plateau. The expression of iNOS was
also time-dependent. It is detectable ¢rst at 15 h after GITR
activation, peaks at 32 h, and is undetectable by 46 h (Fig. 4).
However, released NO32 was detectable after 8 h stimulation
with GITR and the level of NO32 remained at a plateau until
46 h. To clarify that NO32 production and expression of iNOS
were due to GITR, the e¡ect of GITR on expression of iNOS
Fig. 1. SDS^PAGE of puri¢ed rGITR. The extracellular domain of
rGITR was expressed in E. coli using plasmid pET28a. rGITR was
puri¢ed to homogeneity and loaded on 10% SDS^PAGE under re-
ducing (2) and non-reducing conditions (3). Lane 1, molecular size
markers; lane 2, puri¢ed rGITR with 2-mercaptoethanol; lane 3,
rGITR without 2-mercaptoethanol.
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and NO32 production was measured with GITR after preincu-
bation of anti-GITR polyclonal Ab. As shown in Fig. 5, iNOS
induced by GITR was decreased after treatment with anti-
GITR polyclonal Ab. The production of NO32 also decreased.
Monoclonal anti-GITR Ab mAH7 also blocked the response
induced by GITR to a lesser extent. To investigate whether
the action of GITR was related to in£ammation, the antiin-
£ammatory agent dexamethasone was cotreated with GITR
to macrophages. Simultaneous incubation of cells with GITR
and dexamethasone for 24 h inhibits the formation of NO32 in
culture supernatant (Fig. 6). The inhibition of NO32 produc-
tion was dose-dependent. The iNOS induced by GITR also
disappeared by adding dexamethasone to GITR, indicating
that GITR is proin£ammatory rather than antiin£ammatory.
Fig. 2. A: FACS scan of GITR. Raw 264.7 cells (a) and mouse peritoneal macrophages (b) were incubated with rabbit preimmune serum or
polyclonal rabbit anti-GITR Ab for 30 min on ice, washed three times, and ¢nally incubated with FITC-conjugated goat anti-rabbit IgG (peak
2). Cells treated with preimmune serum were used as an isotype control (peak 1). B: FACS scan of GITR ligand. Raw 264.7 cells (a) and
mouse peritoneal macrophages (b) were incubated without (peak 1) or with histidine-tagged GITR, monoclonal anti-histidine Ab (peak 2), and
FITC-conjugated goat anti-mouse IgG each for 30 min on ice for GITR ligand detection. Cells were washed three times after each incubation.
The results are representative of three experiments.
Fig. 3. Dose-dependent production of NO32 by GITR in mouse
macrophage RAW 264.7 cells. Cells were treated with GITR at var-
ious concentrations (0.01, 0.1, 0.2, and 0.5 Wg/ml) for 24 h, followed
by the Griess reagent assay for NO32 . The data shown represent the
mean þ S.D. of three independent assays. The cells used in the NO32
assay were subjected to electrophoresis and Western blot analysis
using iNOS-speci¢c Ab as described in Section 2.
Fig. 4. Time-dependent production of NO32 by GITR in mouse
macrophage RAW 264.7 cells. Cells were treated with 0.1 Wg/ml of
GITR for the indicated incubation times, followed by the Griess re-
agent assay for NO32 . The data shown represent the mean þ S.D. of
three independent assays. The cells used in the NO32 assay were
subjected to electrophoresis and Western blot analysis using iNOS-
speci¢c Ab as described in Section 2.
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3.4. Veri¢cation of GITR activities
We wanted to verify that the observed e¡ects of GITR on
macrophages were genuine and not due to some non-speci¢c
activation or endotoxin contamination associated with the
GITR protein preparation. E¡ects of GITR protein isolated
from di¡erent sources were tested: GITR proteins produced
by the baculovirus expression system as a fusion protein with
a polyhistidine tag and those by HEK 293 cells as a fusion
protein with Fc. They induced expression of iNOS and NO
production as e⁄ciently as did the E. coli-produced GITR
protein (Fig. 7A). In addition, we tested the e¡ects of GITR
after coating the plates with GITR-Fc and GITR-histidine.
No di¡erences in NO production were found in either immo-
bilized or soluble GITR stimulation (data not shown). We
also examined whether GITR could induce iNOS and NO
production in thioglycollate-elicited murine peritoneal macro-
phages. Peritoneal macrophages were also activated by bacu-
lovirus-produced GITR, expressed iNOS, and generated NO
more e⁄ciently than did Raw 264.7 cells (Fig. 7B).
4. Discussion
GITR was described as a new member of the TNF^nerve
growth factor receptor family and considered to have a T
lymphocyte-related activity that control apoptosis in T cells
[1]. Human TR11 (AITR), a full length cDNA from a human
activated T cell cDNA library, has 55% identity with murine
GITR at the amino acid level [5]. Although the high degree of
Fig. 5. E¡ect of anti-GITR Ab on NO32 production by GITR in mouse macrophage RAW 264.7 cells. GITR was preincubated with monoclo-
nal anti-GITR Ab (mAH7) (Ab1, 20 Wl ; Ab2, 50 Wl of hybridoma supernatants) (A) or with polyclonal anti-GITR Ab (Ab1, 30 Wl ; Ab2, 50 Wl
of serum) (B) for 1 h. Then cells were treated with GITR þ mAH7 or polyclonal anti-GITR Ab for 24 h, followed by the Griess reagent assay
for NO32 . The data shown represent the mean þ S.D. of three independent assays. The cells used in the NO
3
2 assay were subjected to electro-
phoresis and Western blot analysis using iNOS-speci¢c Ab as described in Section 2.
Fig. 6. E¡ect of dexamethasone on NO32 production by GITR in
mouse macrophage RAW 264.7 cells. Cells were treated with
GITR þ dexamethasone (D1, 1037 M; D2, 1036 M) for 24 h, fol-
lowed by the Griess reagent assay for NO32 . The data shown repre-
sent the mean þ S.D. of three independent assays. The cells used in
the NO32 assay were subjected to electrophoresis and Western blot
analysis using iNOS-speci¢c Ab as described in Section 2.
Fig. 7. E¡ects of other GITR preparations on NO32 production by
mouse macrophage RAW 264.7 cells (A) or mouse peritoneal mac-
rophages (B). Raw 264.7 cells were treated with GITR-Fc, GITR-
His from baculovirus (GITRh), and GITR-His from E. coli (GITR)
at 0.5 Wg/ml for 8 and 15 h, followed by the Griess reagent assay
for NO32 . Peritoneal macrophages were treated with 0.1 Wg/ml of
GITRh for 4, 8, 15, or 24 h. The data shown represent the
mean þ S.D. of three independent assays. The cells used in the NO32
assay were subjected to electrophoresis and Western blot analysis
using iNOS-speci¢c Ab as described in Section 2.
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sequence conservation between human and mouse suggests
that AITR is likely to be the human homolog of murine
GITR, they may display di¡erent biological activities, based
on the following reasons. One is that there is a mismatch in
the ¢rst cysteine-rich pseudorepeat between GITR and AITR
and the other is that AITR is not inducible by dexametha-
sone. Although the function of AITR is not known clearly,
AITR has been reported to mediate NF-UB activation
through the TRAF2/NIK pathway like 4-1BB.
We have generated the extracellular domain of rGITR, a
fusion protein with a polyhistidine tag, to investigate the cel-
lular function of GITR. Since GITR ligand is required to
transmit the signal for soluble GITR, the presence of GITR
ligand in Raw 264.7 cells and murine peritoneal macrophages
was demonstrated by FACS. GITR and GITR ligand were
constitutively expressed at relatively low levels. We demon-
strated that soluble GITR activates macrophages to express
a high level of iNOS and generates large amounts of NO32 in a
time- and dose-dependent manner. Production of NO32 was
detectable at 10 ng/ml of GITR and reached a plateau above
100 ng of GITR activation after 24 h stimulation. The latter
condition was used to follow NO32 production assays. Induc-
tion of iNOS and NO production by GITR were also ob-
served in murine peritoneal macrophages.
Transduction of signal through the ligand has been also
suggested for the OX40, CD40, CD30, and 4-1BB [21^23].
Soluble 4-1BB induces monocyte activation by expression of
IL-6, IL-8, and TNF-K via bidirectional signaling [24].
Although GITR ligand has not been cloned yet, the presence
was demonstrated by FACS. In this study, we showed that
GITR ligand system induced macrophage activation by ex-
pression of iNOS, and this could be mediated by signaling
through the ligand/receptor.
The expression level of iNOS was lowered by monoclonal
anti-GITR Ab (mAH7) or polyclonal anti-GITR Ab, suggest-
ing that the observed phenomena were due to GITR. The
blocking e¡ect by mAH7 was lower than that by polyclonal
anti-GITR Ab, probably due to its low a⁄nity. When detect-
ing surface GITR in macrophages by FACS analysis, mAH7
showed a lower a⁄nity than polyclonal anti-GITR Ab. We
are now working to generate more mAbs of GITR with high
a⁄nities. It is not known whether the induction of NOS is
caused directly by GITR or indirectly by early secreted cyto-
kines, if any, after GITR stimulation. Further work is in
progress to determine early events by GITR stimulation and
to elucidate the role of GITR and GITR ligand in vivo.
The pro¢le of iNOS expression is similar to that induced by
migration inhibitory factor (MIF), which was found to in£u-
ence a number of macrophage functions [25]. It had been
reported that immune cells secreted MIF in response to phys-
iological increases in glucocorticoid levels, and in turn, MIF
can overcome the immunosuppressive e¡ects of steroids on
cytokine production and cellular activation [26]. It is generally
accepted that immune cell responsiveness is controlled by an
MIF/glucocorticoid dyad. It has been reported that besides
GITR and MIF, lipopolysaccharide, TNF-K and IFN-Q can
activate iNOS in in vitro macrophage systems [27,28]. Since
the GITR preparation contained 6 0.4 EU/mg of endotoxin
as determined by the E-Toxate assay, NO production could
not be due to contaminated endotoxin of GITR.
Simultaneous incubation of cells with GITR and an antiin-
£ammatory agent, dexamethasone, inhibits the formation of
NO32 in culture supernatant and induction of iNOS in a dose-
dependent manner. The induction of iNOS and NO produc-
tion in macrophages by MIF and IFN-Q was also inhibited by
adding dexamethasone [25]. It is generally known that gluco-
corticoid could a¡ect the transcription of a number of nuclear
proteins to inhibit the expression of iNOS. The activation of
macrophages for iNOS expression by GITR could share a
common transcriptional mechanism with MIF and IFN-Q.
Among the widely used drugs in antiin£ammatory therapy,
glucocorticoids are e¡ective in reducing in£ammation, partly
due to controlling NO generation. In contrast, soluble GITR
resulted in the opposite e¡ect.
In summary, we have shown that GITR activates macro-
phages to express a high level of iNOS and produce large
amounts of NO in a time- and dose-dependent manner.
GITR could serve as a physiological counterregulatory medi-
ator and counteract the immunosuppressive e¡ects by gluco-
corticoids.
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